This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (29)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Conflict of Interest  • Medical Education  • Medical Ethics  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Alan F. Holmer, JD

JAMA. 2001;285:2012-2014.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Just as it leads in biomedical innovation, the pharmaceutical industry is proud to play a leading role in sponsoring continuing medical education (CME) for physicians—an effort that serves the overriding mutual interest to ensure that patients receive the most up-to-date and appropriate care.

The accelerating pace of biomedical progress, in such fields as biochemistry, molecular biology, cell biology, immunology, genetics, and information technology, makes it more imperative than ever for physicians to stay abreast of the latest medical innovations and treatments. Particularly at a time when patients are increasingly demanding and receiving more health care information, the pharmaceutical industry and the medical profession are obligated to do all they can to ensure that physicians, the key prescribers of prescription medicines in the health care system, are thoroughly informed about the latest medical developments.

Industry-supported conferences, seminars, and symposia are helping physicians to provide the best, most . . . [Full Text of this Article]

Author Affiliation: Pharmaceutical Research and Manufacturers of America (PhRMA), Washington, DC.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Separating Continuing Medical Education From Pharmaceutical Marketing
Arnold S. Relman
JAMA. 2001;285(15):2009-2012.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmaceutical industry financial support for medical education: benefit, or undue influence?
Brody
J Law Med Ethics 2009;37:451-460.
 

Conflict of Interest in Clinical Practice
Tonelli
Chest 2007;132:664-670.
ABSTRACT | FULL TEXT  

A National Survey of Physician-Industry Relationships
Campbell et al.
NEJM 2007;356:1742-1750.
ABSTRACT | FULL TEXT  

Current Status of Medical Grand Rounds in Departments of Medicine at US Medical Schools
Mueller et al.
Mayo Clin Proc. 2006;81:313-321.
ABSTRACT | FULL TEXT  

Physician Strategies to Reduce Patients' Out-of-pocket Prescription Costs
Alexander et al.
Arch Intern Med 2005;165:633-636.
ABSTRACT | FULL TEXT  

Promotion and Prescribing of Hormone Therapy After Report of Harm by the Women's Health Initiative
Majumdar et al.
JAMA 2004;292:1983-1988.
ABSTRACT | FULL TEXT  

Ethical Concerns in Industry Support of Continuing Medical Education: The Con Side
Packer and Parke
Arch Ophthalmol 2004;122:773-776.
FULL TEXT  

Developing and Implementing a Program of Grand Rounds for Internists That Is Free of Commercial Bias
McMahon et al.
ANN INTERN MED 2003;139:77-78.
FULL TEXT  

Defending Professional Independence: ACCME's Proposed New Guidelines for Commercial Support of CME
Relman
JAMA 2003;289:2418-2420.
FULL TEXT  

Physician-Industry Relations. Part 2: Organizational Issues
Coyle and for the Ethics and Human Rights Committee, America
ANN INTERN MED 2002;136:403-406.
ABSTRACT | FULL TEXT  

Reforming Graduate Medical Education
Bell
JAMA 2002;287:715-715.
FULL TEXT  

ACCME standards for commercial support--time for a change?
Parmley
J Am Coll Cardiol 2001;38:916-917.
FULL TEXT  

The Pharmaceutical Industry and Continuing Education
Dermksian et al.
JAMA 2001;286:302-304.
FULL TEXT